Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
about
Decitabine in the treatment of myelodysplastic syndromesCpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2DNA and the chromosome - varied targets for chemotherapyA phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genesDown-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter regionEpigenetics of cervical cancer. An overview and therapeutic perspectivesThe role of chromatin modifications in somatic embryogenesis in plantsOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaHypermethylation of gene promoters in hematological neoplasiaProcainamide Inhibits DNA Methylation and Alleviates Multiple Organ Dysfunction in Rats with Endotoxic ShockA folate- and methyl-deficient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 ratsA novel method to quantify local CpG methylation density by regional methylation elongation assay on microarrayA randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine.Demethylating Agents in the Treatment of CancerWnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II reportEpigenetic changes in the myelodysplastic syndrome.Epigenetic regulation of the placental HSD11B2 barrier and its role as a critical regulator of fetal development.Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer.Synthesis of stable-isotope enriched 5-methylpyrimidines and their use as probes of base reactivity in DNA.Aberrant DNA methylation in malignant melanomaOxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2).Gene repair and transposon-mediated gene therapy.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategiesDeep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family membersThe effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromesMethylation determines fibroblast activation and fibrogenesis in the kidney.Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinomaHypomethylation: one side of a larger picture.Histone acetylation and gastrointestinal carcinogenesis.Chronic myelogenous leukemia: a review and update of therapeutic strategies.HOXA11 gene is hypermethylation and aberrant expression in gastric cancer.Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes?Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
P2860
Q24641906-C4594310-C41E-48FA-A013-C6C376CA118EQ24684224-872179AF-C66F-4E97-850D-2D846E417F73Q24792540-23A06DC6-7AB4-4656-B0CE-F34E3F24CC45Q24804876-CD8AAF49-F11F-4D49-AAFC-4ACCCC39823DQ24810666-FD429753-E87F-4BF9-89A2-4CC5BAA0353EQ24812104-3321555A-88F2-40DE-8D2B-DB5F7CF4CDBFQ26782771-10314FA9-337A-4B23-B868-1E484BBB8CF7Q28084813-367EA020-163B-4094-B2F4-4338C21DBA5BQ28216777-EF46244A-253A-4B03-874F-6374632BB0A6Q28554338-EE9D15E7-46AE-472E-918C-905A2502034CQ28566367-72B6172E-965C-4805-8F5A-D704E5C923E8Q33317627-2F78B341-EBB5-4FA0-8060-83414DAB8814Q33402882-C93A70DF-F3FF-44B0-8398-F655AC485B31Q33408105-2E0E1034-98F8-47F8-AFB4-8F435FAFB737Q33615323-EEE2833E-FE62-47EB-BFD1-1B6F5C2FD15FQ33678040-EB426E40-F0F3-40E8-B495-9391E86249E5Q33685717-41E060EF-D2B0-4C73-8F47-461B70538C52Q33744733-7125EBD8-408C-4747-99E7-6276FF00A181Q33767309-60D82ABE-F2DE-4C2B-BC12-758F62356FB7Q33784581-D588F391-ECE5-42C7-9806-294A30BE34E6Q33995610-153A266F-88A6-4FA3-A6E7-4DFD3849070AQ34025724-7EAE0E70-C164-4EDF-8566-EFE9CAC598BFQ34273735-C9A5F2B2-DDFD-4319-A217-CFB2BDEF8EC5Q34319824-B6AE9B11-2E9C-40BC-8A84-E562130273A5Q34367213-F85F91FB-B651-4743-8CF2-2A1656517419Q34516587-A577DAF3-0A1A-4BF0-8613-8FEB0FC8E375Q34550062-47D7F3F8-2BFB-4616-8D8D-59BDD895A26EQ34565709-6E7A5985-92EA-4EAA-AE53-0F6FD5A421CFQ34768789-FE634413-163D-4CDC-B58D-ABF84AC7EB91Q34894993-46689CD6-B960-46F7-B3A9-F6C79E5C6539Q34979774-885566B5-C0C7-41C2-8638-D8E209AAF646Q35019643-15B7F8A2-7CA5-4409-B441-F90FDE6A3D22Q35034638-9CCF1B7C-B78E-49A6-B557-7C195AA8CE23Q35103419-EFAECDDB-2E2F-45E2-B439-A30D156A2E88Q35118465-04B99A96-ECF2-477F-9A63-90BF090C7F4DQ35118529-4D4320FC-322E-44EC-B9D9-BD47C6B91C4DQ35184329-1CA46046-C2BB-4E49-8412-D7E7083BC66AQ35189387-9B0695EC-9D49-4D75-82B0-E69D0C777876Q35217405-2B49DBA9-3058-49B7-B37E-77F7B67B0CA2Q35224437-F42B9024-4AD1-4483-BDDE-F6E6713E269D
P2860
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@ast
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@en
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@nl
type
label
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@ast
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@en
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@nl
prefLabel
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@ast
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@en
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
@nl
P1476
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications
@en
P2093
H M Kantarjian
P304
P356
10.7326/0003-4819-134-7-200104030-00011
P407
P577
2001-04-01T00:00:00Z